SESSION 4 – Clinical development of NTRK inhibitors – Part 1
Present results with larotrectinib
Date
23 Nov 2020Session
SESSION 4 – Clinical development of NTRK inhibitors – Part 1Presenters
U. N. Lassen, DKResources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Multi Kinases inhibitors with NTRK as a possible target
Presenter: M. Tahara, JP
Session: SESSION 4 – Clinical development of NTRK inhibitors – Part 1
Resources:
Slides
Webcast
Tolerance profile and recommendation for use
Presenter: J. Lim, SG
Session: SESSION 4 – Clinical development of NTRK inhibitors – Part 1
Resources:
Slides
Webcast